Karyopharm presents Selinexor data at ASH


Karyopharm Therapeutics' (KPTI) Selinexor "showed preliminary evidence of anti-cancer activity as a single agent" in most relapsed/refractory NHL and CLL patients from a cohort comprised of those with progressive disease on entry.

Data summary from the Phase 1 trial in advanced hematologic malignancies: PRs, 27%; SD, 50%; tumor shrinkage in 17 of 18 patients. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs